PAION Announces Patient Recruitment For Phase IIa Study With Its Short Acting Anesthetic/Sedative CNS 7056 Successfully Completed
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract. “Again our development team has beaten our expectations. We will be able to provide headline data by November,” commented Dr.
Related Posts
Tags: 7056, acting, anestheticsedative, completed, paion, patient, phase, recruitment, short, study, successfully
This entry was posted on Sunday, September 13th, 2009 at 12:09 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.



